Cardiotoxicity publications have been increasing at an astounding pace since the 1970s. If there was a time to be bringing a cardioprotective agent with historic clinical efficacy to market, it is now. 2024 is on track to being another massive year for cardiotoxicity research - hopefully publications relating to Zantrene can be in that mix. For the record, publications on FTO is only 4000.
Cardioprotection thread, page-343
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |